Serna Bio is an AI-enabled drug discovery company that focuses on developing small molecules to modulate translation and splicing for challenging-to-drug targets. The company's innovative approach leverages synthetic biology, machine learning, and massively multiplex screening to address the complexities of drugging the transcriptome. By combining in vitro assays and machine learning tools, Serna Bio maps RNA architecture to identify druggable RNA motifs. With the world's largest database of functional RNA structures and unique chemical libraries, Serna Bio powers both internal initiatives and external collaborations in the pursuit of tackling diseases with high unmet medical needs.